<SEC-DOCUMENT>0001501697-25-000041.txt : 20251105
<SEC-HEADER>0001501697-25-000041.hdr.sgml : 20251105
<ACCEPTANCE-DATETIME>20251105080551
ACCESSION NUMBER:		0001501697-25-000041
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251105
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251105
DATE AS OF CHANGE:		20251105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		251451884

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xfor-20251105.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f84172b7-0d5e-49bb-86f4-d539a2b10b62,g:2753f2c3-a274-44d6-8bd3-b86e849d3ff6,d:0bb0183ad5ec40dab399810887137fae-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20251105</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20251105.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-05</xbrli:startDate><xbrli:endDate>2025-11-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0bb0183ad5ec40dab399810887137fae_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.068%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"/><td style="width:48.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:100%">FORM  </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr><tr style="height:8pt"><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 5, 2025</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.603%"><tr><td style="width:1.0%"/><td style="width:22.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.600%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:22pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">X4 PHARMACEUTICALS, INC.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.781%"><tr><td style="width:1.0%"/><td style="width:33.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38295</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">27-3181608</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.373%"><tr><td style="width:1.0%"/><td style="width:20.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.348%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">61 North Beacon Street,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">4th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Boston,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">02134</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">857</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">_______________________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule  13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.252%"><tr><td style="width:1.0%"/><td style="width:34.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.967%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).          Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0bb0183ad5ec40dab399810887137fae_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.575%"><tr><td style="width:1.0%"/><td style="width:15.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Condition.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On November 5, 2025, X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results and other business highlights for the third quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The information furnished under this Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-991pressreleasenovember.htm">Press Release issued by X4 Pharmaceuticals, Inc., dated November 5, 2025.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0bb0183ad5ec40dab399810887137fae_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.113%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date:  November 5, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David H. Kirske</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">David H. Kirske</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-991pressreleasenovember.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8359142c554c417eb9f1d1f1ed0b06f4_1"></div><div style="min-height:90pt;width:100%"><div style="text-align:right"><font><br></font></div><div><img alt="x4logo.jpg" src="x4logo.jpg" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:118px"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:128%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:128%">Exhibit 99.1</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:127%">X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:127%">Company&#8217;s strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Previously announced workforce reductions resulted in $13M annualized cost savings</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Successful completion of two financial transactions totaling $240.3M&#59; cash runway now extends to the end of 2028</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">BOSTON, November 5, 2025 (GLOBAL NEWS WIRE) &#8211; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">X4 Pharmaceuticals</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (Nasdaq&#58; XFOR), a company driven to improve the lives of people with rare hematology diseases, today reported financial results for the third quarter ended September 30, 2025 and provided a corporate update. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;The third quarter of 2025 was a time of corporate restructuring at X4 with the start of a new leadership team and a renewed focus on chronic neutropenia,&#8221; said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. &#8220;With a strengthened financial position through two successful financings totaling $240.3 million, our primary focus is now on the completion of the 4WARD Phase 3 pivotal trial of mavorixafor in patients with moderate and severe chronic neutropenia, which has a potential addressable market of 15,000 patients in the US. With a cash runway to the end of 2028, we are now positioned to unlock mavorixafor&#8217;s full potential and to establish X4 as a world-class rare hematology company.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Recent Accomplishments and Updates</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Since early August, the Company has initiated a number of measures to restructure its operations&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10.8pt">A shift in the primary focus of the Company to the successful completion of the 4WARD Phase 3 pivotal trial of mavorixafor in patients with moderate and severe chronic neutropenia. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">A deprioritization of the commercialization of mavorixafor (XOLREMDI) for patients with WHIM syndrome, while maintaining patient access.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">A 50% reduction in the workforce (expected to generate approximately $13 million in annualized cost savings) with continued cost cutting measures.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">An increase in the enrollment target for the pivotal Phase 3 4WARD study to 176 patients with enrollment now expected to be completed in third quarter of 2026.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">The promotion of John Volpone to the role of Chief Operating Officer, in addition to his responsibilities as President.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">Dr. Adam Craig expanded his role to include oversight of clinical development activities. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Since August, the Company raised $240.3 million in gross proceeds from two successful financings&#58; the closing of a $155.3 million underwritten public offering and an $85 million upsized private placement.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">With a strengthened cash runway to the end of 2028, X4 is now expected to be able to complete the 4WARD trial, file a potential sNDA for the chronic neutropenia indication, and, if successful, launch mavorixafor in this new indication by the end of 2028.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:128%">Third Quarter and Recent Financial Results</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net product sales of $1.6 million and $4.3 million for the three and nine months ended September 30, 2025, respectively, were entirely attributable to XOLREMDI product sales in the United States. Net product sales were $0.6 million and $1.1 million for the three and nine months ended September 30, 2024, respectively. License and other revenue of $0.2 million and $28.3 million for the three and nine months ended September 30, 2025, respectively, were entirely attributable to the Company's Norgine out-licensing agreement. Operating loss was $27.5 million and $34.5 million for the three months ended September 30, 2025 and 2024, respectively, and $63.2 million and $0.7 million for the nine months ended September 30, 2025 and 2024, respectively. The decrease in operating loss between the three-month periods ended September 30, 2025 and 2024 was primarily attributable to the impact of our 2025 Strategic Restructuring activities. Operating expenses for the nine months ended September 30, 2024 are net of a gain of $105.0 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:right"><font><br></font></div><div><img alt="x4logo.jpg" src="x4logo.jpg" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:118px"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:128%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">million realized on the sale of a priority review voucher. Exclusive of this gain, the decrease in operating loss between the nine-month periods ended September 30, 2025 and 2024 was primarily attributable to the impact of the Company's strategic restructuring activities undertaken in 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss for the three months ended September 30, 2025 was $29.8 million, or $0.69 for basic and diluted loss per share, compared to net loss of $36.7 million, or $5.48 for basic and diluted loss per share, for the same period in 2024. Net loss for the nine months ended September 30, 2025 was $55.3 million, or $2.87 for basic and diluted loss per share, compared to net income of $2.4 million, or $0.35 for basic and diluted income per share, for the same period in 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cash, cash equivalents and short-term investments totaled $122.2 million for the period ended September 30, 2025. On October 27, 2025, the Company completed a public offering with net proceeds of $145.6 million, which management believes will enable the Company to fund its operations into the end of 2028.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Chronic Neutropenia and Mavorixafor </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Chronic neutropenia is a primary, rare blood condition lasting more than three months, persistently or intermittently, and characterized by low levels of circulating neutrophils and increased risk of serious and life-threatening infections and reduced quality of life due to abnormally low levels of neutrophils circulating in the blood. Neutrophils are retained in the bone marrow by the CXCR4&#47;CXCL12 axis, creating a reserve of cells. Downregulation of the CXCR4 receptor by mavorixafor, an orally active CXCR4 antagonist, has been shown to mobilize functional neutrophils from the bone marrow into the peripheral blood across multiple disease states. The level of circulating neutrophils is typically measured by drawing blood to determine the absolute neutrophil count (ANC).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About the 4WARD Clinical Trial </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The 4WARD trial is a global, pivotal Phase 3 clinical trial (NCT06056297) evaluating the efficacy, safety, and tolerability of oral, once-daily mavorixafor (with or without G-CSF) in patients with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who are experiencing recurrent and&#47;or serious infections. The 52-week trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll 176 patients with confirmed trough ANC levels less than 1,000 cells per microliter at baseline screening and histories of two or more serious and&#47;or recurrent infections in the prior year. The primary endpoints of the study are the reduction in annualized infection rate and positive ANC response.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:127%">About X4 Pharmaceuticals</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI&#174; in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in patients with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.x4pharma.com.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:127%">X4 Forward Looking Statements </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; or other similar terms or expressions that concern X4&#8217;s expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding the expected cost savings from the workforce reduction, the expected results of the restructuring of business operations, the sufficiency of the Company&#8217;s cash resources and its expected cash runway, the potential addressable market for moderate and severe chronic neutropenia, the timing for launch of mavorixafor and future plans for the Company. Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4&#8217;s control, which could cause actual results to differ materially from </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:right"><font><br></font></div><div><img alt="x4logo.jpg" src="x4logo.jpg" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:118px"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:128%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">those contemplated in these forward-looking statements, including the risks that&#58; the workforce reduction does not result in the anticipated cost savings described herein&#59; the results of the restructuring of business operations are not as anticipated&#59; and other risks and uncertainties, including those described in the section entitled &#8220;Risk Factors&#8221; in X4&#8217;s most recent Annual Report on X4&#8217;s Form 10-K, as well as in other filings X4 makes with the Securities and Exchange Commission, including its quarterly report on Form 10-Q, from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:127%">X4 Investor Contact&#58;</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:127%">IR&#64;X4pharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:127%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:128%">(Tables Follow)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">X4 PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:43.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,293&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,545&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,337&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,173&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,941&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,586&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,660&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,134&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,373&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of non-financial asset</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,274&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,060&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,729&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,509)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,500)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,184)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(686)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,336)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,181)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,951&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before provision for income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,845)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,681)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,233)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,815)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,696)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,274)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share- basic</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.48)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.87)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding-basic</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,273&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,696&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,243&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,681&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share- diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.48)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.87)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding-diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,273&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,696&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,243&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,687&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:right"><font><br></font></div><div><img alt="x4logo.jpg" src="x4logo.jpg" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:118px"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:128%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Balance Sheet Data (unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.388%"><tr><td style="width:1.0%"></td><td style="width:59.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(amounts in thousands)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,632&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,699&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,562&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,361&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,299&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,298&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,555&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,447&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,619&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,149&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>xfor-20251105.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f84172b7-0d5e-49bb-86f4-d539a2b10b62,g:2753f2c3-a274-44d6-8bd3-b86e849d3ff6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20251105" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20251105">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20251105_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20251105_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.x4pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>xfor-20251105_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f84172b7-0d5e-49bb-86f4-d539a2b10b62,g:2753f2c3-a274-44d6-8bd3-b86e849d3ff6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_24ac552e-16f7-4b75-b684-ef2cd4a8a14e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5770b497-41e3-4a16-bc9e-b7ed19d148a9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_75e929d8-ad9b-4cf0-a793-a63d286a0c5b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_15340c93-094d-4cbf-bb7c-e1dec1df8115_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_61494909-710e-45e8-b593-7fe3b4589c6f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9620c0a8-e4ae-4e60-b984-2bae5bbe2e59_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_c0b663b4-053b-4570-9ac8-4fe2352c11ee_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_33b1634e-153b-4ebb-b6bf-3f9d6b5d1d64_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_07311de9-cc44-48eb-a9a0-096536cb926d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_5592eb49-0ee7-4283-aa9e-9b9fc2c05cdc_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8963321d-9153-4947-b808-23b27a80bdd7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_e07c0ce0-9d61-433f-a3ad-4403dc8f006a_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_4908d6ee-3d09-41fb-93c3-3456155af1dd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_70e38a11-53b1-4d6e-b499-4a88d67791ca_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_07ec6152-7e81-4114-a6c4-af544098a199_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a5097641-39f4-4bd9-a8e7-be4f2791fff9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8698a3ea-4dae-49c9-96d5-cf77a2bb5f72_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_21a134f9-c35e-4f50-83d2-721bfacd9c37_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8d58c59e-0b0f-4e3f-89e4-a003ad37e9ed_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b1c78554-22da-46c4-969c-4feee34d7a47_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7986e35d-add7-4ace-88e7-d394eae05df7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_4fb27c5a-7644-49b8-8d1a-ca78aed1a565_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ef3c9df5-310d-4f82-8181-12063d370293_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_509e75ba-7961-40bd-8f04-c223933069cf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>xfor-20251105_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f84172b7-0d5e-49bb-86f4-d539a2b10b62,g:2753f2c3-a274-44d6-8bd3-b86e849d3ff6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20251105.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_13a82763-9040-46b2-8329-eb070876b3e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_DocumentType_13a82763-9040-46b2-8329-eb070876b3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_54f32ff6-83a1-4e35-b0f5-521baeb58992" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_DocumentPeriodEndDate_54f32ff6-83a1-4e35-b0f5-521baeb58992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b508c0da-84a5-467f-94e9-4cae166aa4a3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityRegistrantName_b508c0da-84a5-467f-94e9-4cae166aa4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_90c58a71-3ff5-463b-be79-3ed051390586" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityIncorporationStateCountryCode_90c58a71-3ff5-463b-be79-3ed051390586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7a1175fa-7910-4d0b-9b5d-14bcb58842bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityFileNumber_7a1175fa-7910-4d0b-9b5d-14bcb58842bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e6c4ee28-7721-4669-a38d-f09e679a8bb7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityTaxIdentificationNumber_e6c4ee28-7721-4669-a38d-f09e679a8bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_61dc97fc-0cd6-4a06-b679-36572b2c255a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityAddressAddressLine1_61dc97fc-0cd6-4a06-b679-36572b2c255a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_c86ad3ad-a864-4961-9d45-e21d8f25a035" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityAddressAddressLine2_c86ad3ad-a864-4961-9d45-e21d8f25a035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1e4c78ed-0d7d-4d60-8fa9-0705d2c15e6d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityAddressCityOrTown_1e4c78ed-0d7d-4d60-8fa9-0705d2c15e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a9688936-795d-495d-b921-22c08eeaf077" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityAddressStateOrProvince_a9688936-795d-495d-b921-22c08eeaf077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c15c4145-625e-4047-842d-8d4b9e243fc9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityAddressPostalZipCode_c15c4145-625e-4047-842d-8d4b9e243fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e9480379-ab61-449d-a276-296e1ee8a464" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_CityAreaCode_e9480379-ab61-449d-a276-296e1ee8a464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fb9f4ac7-7ac6-4a76-8b1a-84621519a4d6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_LocalPhoneNumber_fb9f4ac7-7ac6-4a76-8b1a-84621519a4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_98602618-1ad9-486a-9e41-e94575cde135" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_WrittenCommunications_98602618-1ad9-486a-9e41-e94575cde135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_257ee3e5-8dac-423d-8edb-cc7ade44415c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_SolicitingMaterial_257ee3e5-8dac-423d-8edb-cc7ade44415c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_23ea4ba3-4664-4d22-97c6-87eecc6ac535" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_PreCommencementTenderOffer_23ea4ba3-4664-4d22-97c6-87eecc6ac535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7224f64b-3809-47d3-84f3-24e391bf7a72" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7224f64b-3809-47d3-84f3-24e391bf7a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_eff3554c-d04d-4248-b2ec-85c317d6bec8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_Security12bTitle_eff3554c-d04d-4248-b2ec-85c317d6bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6ef8e8f6-76fb-44f2-aa3d-236fb2cc78ce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_TradingSymbol_6ef8e8f6-76fb-44f2-aa3d-236fb2cc78ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1f8566a3-d59a-41bd-be1f-e3160d54131e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_SecurityExchangeName_1f8566a3-d59a-41bd-be1f-e3160d54131e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fd8db17c-7828-42ba-95a8-befd213a083b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityEmergingGrowthCompany_fd8db17c-7828-42ba-95a8-befd213a083b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_fd31212d-3a30-491e-aaa3-d7bc2e2783b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityExTransitionPeriod_fd31212d-3a30-491e-aaa3-d7bc2e2783b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_94486d24-40f7-471b-aeaa-d39305146777" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_EntityCentralIndexKey_94486d24-40f7-471b-aeaa-d39305146777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0043a3c1-8fdc-48b2-bf8f-eb6eff67634f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52b78672-b9c4-4215-a9ac-d0237bc35fed" xlink:to="loc_dei_AmendmentFlag_0043a3c1-8fdc-48b2-bf8f-eb6eff67634f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>x4logo.jpg
<TEXT>
begin 644 x4logo.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #1 0T# 2(  A$! Q$!_\0
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M,/AY<?$KQ/'ID;O;V:+YEU<JA/EIZ>S'H,U]N:5IMOHVG6MC:1B&UMXUBC0
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M$7AW_KG)_P"C7KX1_P""B>EWEM\>+2^FMI$LKK1X$MYV&$D9'?>%/?;N7/\
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M\WG.523G+5L*4 D@8R2<8]Z2O9/V</AJOBO7GUV_B632]-?:D<B!EFGQD?\
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M'0YK/!8GVB]G/XD;9I@E1?MZ7PO\#GJ***]4^?"BBB@ HHHH **** "BBB@
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M!VJ;2OV5/&47[7UOJD\13X1F9/%\ME),)X9M;%NL)WH6W+*'S*C ,JA !@G
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MB+Q]^U=\6O "^,==T'1SX-TV6S?2[G8^GSR32!YX 0560A0"<5X+%X-\>O\
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M@#O4NI.2M)W*A0I0=XQ28ZBBBH.@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  05,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xfor-20251105.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="xfor-20251105.htm">xfor-20251105.htm</File>
    <File>xfor-20251105.xsd</File>
    <File>xfor-20251105_lab.xml</File>
    <File>xfor-20251105_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "xfor-20251105.htm": {
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20251105",
   "dts": {
    "inline": {
     "local": [
      "xfor-20251105.htm"
     ]
    },
    "schema": {
     "local": [
      "xfor-20251105.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20251105_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20251105_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.x4pharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xfor-20251105.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xfor-20251105.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001501697-25-000041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001501697-25-000041-xbrl.zip
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MJ3_>]B@]BL7J\/NUJ_P;^#%(PN#3_P-02P,$%     @ N4!E6PZ"20!*$
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M:]F5 9-!E\,6;\YBKM8'TW"^5WNX>L(M6%M!KBF W@Y&ET"D\<;7>RII\MI
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H<BTR,#(U,3$P-5]P<F4N>&UL4$L%!@     %  4 4 $  /D_      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>xfor-20251105_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xfor-20251105.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2025-11-05</startDate>
            <endDate>2025-11-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001501697</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">X4 PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38295</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">61 North Beacon Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Boston,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">529-8300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
